Loading data for DNLI — first visit, this takes a few seconds.

提醒

Denali Therapeutics Inc. (DNLI)

NasdaqGS: DNLI · 即時價格 · USD

24.00

-0.67 (-2.72%)

收盤價： Aug 28, 2026, 3:59 PM

24.00

+0.00%

盤後: 7:30 PM

股價、關鍵數字和最新消息，都在這一頁。

-2.72% (1D)

買價	23.94
市值	3.84B
營收 (ttm)	3.6M
淨利（ttm）	-511.45M
	1.00
	-2.84
	n/a
	-9.86
P/B (ttm)	4.59
P/S (ttm)	1064.47
財報日期	Nov 5, 2026

賣價	24
成交量	807,562
20 日平均成交量	1,679,780
開盤價	24.42
前收盤價	24.67
當日區間	23.92 - 24.61
52 週範圍	12.58 - 27.30
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Dec 8, 2017

員工 503

證券交易所 NasdaqGS

股票代號 DNLI

網站 https://www.denalitherapeutics.com

完整的公司簡介

財務表現

Denali Therapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -512.54M，較前期增加 21.23%。

財務報表

財報驚奇

Denali Therapeutics 已於 Aug 6, 2026 公布季度財報：

營收為 $3.6M 低於預期 $0, 年增 Infinity% 成長.
每股盈餘為 -0.68 低於預期 -0.21, 年增 5.56% 成長.

下次財報發布

Denali Therapeutics Inc. 的下次財報預計於 Nov 5, 2026, 盤中。
分析師預估營收 ... 升級

新聞動態

1 週前 · Zacks

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

1 週前 · Zacks

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

2 週前 · Motley Fool

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

AVLAYAH revenue hit $3.6M in first full quarter post-approval.

3 週前 · Moby

Denali Therapeutics Inc. Q2 2026 Earnings Call Summary

Moby summary of Denali Therapeutics Inc.'s Q2 2026 earnings call

3 週前 · MarketBeat

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expande...

第 1 頁，共 2 頁

Denali Therapeutics Inc. (DNLI)